{"protocolSection":{"identificationModule":{"nctId":"NCT04946474","orgStudyIdInfo":{"id":"M2019412"},"organization":{"fullName":"Peking University Third Hospital","class":"OTHER"},"briefTitle":"Clinical Evaluation of the Combination of Symptoms and Symptoms With General Treatment for Acute Hemorrhagic Stroke","officialTitle":"Clinical Evaluation and Study on the Combination of Disease and Syndrome With General Treatment for Acute Hemorrhagic Stroke"},"statusModule":{"statusVerifiedDate":"2021-06","overallStatus":"UNKNOWN","lastKnownStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-06-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-07-01","type":"ACTUAL"},"completionDateStruct":{"date":"2021-09-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-06-27","studyFirstSubmitQcDate":"2021-06-27","studyFirstPostDateStruct":{"date":"2021-06-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-06-27","lastUpdatePostDateStruct":{"date":"2021-06-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Peking University Third Hospital","class":"OTHER"},"collaborators":[{"name":"Beijing Tiantan Hospital","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Objective To evaluate whether Xingnaojing injection combined with Naoxueshu oral liquid can significantly improve the clinical outcome of patients with intracerebral hemorrhage.\n\nSecondary objectives included to evaluate whether combined application of Xingnaojing injection and Naoxueshu oral liquid can promote hematoma absorption or reduce perihematoma cerebral edema in patients with intracerebral hemorrhage","detailedDescription":"Objective To evaluate whether Xingnaojing injection combined with Naoxueshu oral liquid can significantly improve the clinical outcome of patients with intracerebral hemorrhage.\n\nSecondary objectives included to evaluate whether combined application of Xingnaojing injection and Naoxueshu oral liquid can promote hematoma absorption or reduce perihematoma cerebral edema in patients with intracerebral hemorrhage Statistical Methods: The main effective outcomes will be based on a generalized linear model and adjusted for associated confounders."},"conditionsModule":{"conditions":["Acute Hemorrhagic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":520,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Xingnaojing injection + Shuxuetong oral liquid","type":"EXPERIMENTAL","description":"Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).","interventionNames":["Drug: Xingnaojing injection + Shuxuetong oral liquid"]},{"label":"Placebo group","type":"PLACEBO_COMPARATOR","description":"Xingnaojing injection simulation agent + Naoxueshu oral liquid simulation agent treatment was given.","interventionNames":["Drug: Xingnaojing injection + Shuxuetong oral liquid"]}],"interventions":[{"type":"DRUG","name":"Xingnaojing injection + Shuxuetong oral liquid","description":"Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).","armGroupLabels":["Placebo group","Xingnaojing injection + Shuxuetong oral liquid"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"self-care","description":"90 days of self-care (mRS 0-2 points)","timeFrame":"after 90 days"}],"secondaryOutcomes":[{"measure":"NIHSS","description":"NIHSS score improvement on day 14 of onset","timeFrame":"on day 14 of onset"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ① It meets the diagnostic criteria of primary cerebral hemorrhage.\n\n  * Within 72 hours of onset.\n\n    * National Institutes of Health Stroke Scale (NIHSS) score ≥4 points.\n\n      ④ Glasgow Coma Scale (GCS) score \\&gt; Eight points.\n\n      ⑤ Age 18-80. Patient or legal representative informed consent, and sign informed consent.\n\nExclusion Criteria:\n\n* (1) known to Xingnaojing, cerebral hemorrhage or related drug ingredients allergic.\n\n  * The patients with previous stroke history and remaining sequelae affected the outcome assessment, that is, the modified Ranking scale (MRS) score before the onset of stroke was ≥2 points.\n\n    (3) known by amyloid cerebrovascular disease, vascular malformation, aneurysm, blood coagulation dysfunction, anticoagulation and antiplatelet drug treatment, thrombolysis therapy, bleeding after infarction after conversion, haematology, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, and vascular inflammation caused by clear etiology of patients with cerebral hemorrhage or primary intraventricular hemorrhage.\n\n(Note: \"After anticoagulant or antiplatelet therapy\" refers to patients with intracerebral hemorrhage following anticoagulant and antiplatelet therapy, and these patients were excluded from this study.) (4) Patients with traumatic cerebral hemorrhage. (5) patients with active gastrointestinal ulcer or other definite tendency of rebleeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Peking Yniversity Third Hospital","city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083302","term":"Hemorrhagic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M16045","name":"Syndrome","relevance":"LOW"},{"id":"M2405","name":"Hemorrhagic Stroke","asFound":"Hemorrhagic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}